{"id":"renamezin-capsule","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Tendinitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Renamezin is a fluoroquinolone antibiotic that works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and transcription. This leads to disruption of bacterial cell division and death. It is effective against a broad spectrum of gram-positive and gram-negative bacteria.","oneSentence":"Renamezin is an antibiotic that inhibits bacterial protein synthesis by binding to the bacterial ribosome.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:37:08.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (respiratory tract, urinary tract, and other infections)"}]},"trialDetails":[{"nctId":"NCT03788252","phase":"PHASE4","title":"Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Gumi Cha Medical Center","startDate":"2018-11-23","conditions":"Chronic Kidney Diseases","enrollment":150},{"nctId":"NCT02681991","phase":"PHASE4","title":"Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2016-01","conditions":"Chronic Renal Failure","enrollment":110},{"nctId":"NCT02681952","phase":"PHASE4","title":"A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2015-12","conditions":"Chronic Renal Failure","enrollment":153}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Renamezin administration"],"phase":"marketed","status":"active","brandName":"Renamezin capsule","genericName":"Renamezin capsule","companyName":"Daewon Pharmaceutical Co., Ltd.","companyId":"daewon-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Renamezin capsule is a small molecule neurokinin 1 receptor antagonist used to treat conditions such as Chronic Renal Failure and Chronic Kidney Diseases. It is classified as an antagonist and targets the Substance-P receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}